Liver cancer, breast cancer, brain glioma
Conditions
Interventions
Gold Standard:intraoperative frozen
Index test:EndoScell Scanner system scan
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
14 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Liver cancer: (1) Between the ages of 18 and 70; (2) Patients diagnosed with liver cancer before surgery, with a maximum tumor diameter of = 3cm assessed by imaging and no evidence of distant metastasis, and planned for surgical resection; (3) The subjects voluntarily sign the informed consent form or are exempted from signing after being reviewed and approved by the ethics committee. (2) Breast cancer: (1) Between the ages of 18 and 70; (2) Early breast cancer Breast tumor is less than 5 cm, cN 0-1; (3) Not invading the skin, subcutaneous tissue, pectoralis major muscle, and nipple areola complex; (4) There is no clinical or imaging evidence of distant metastasis; (5) The subjects voluntarily sign the informed consent form or are exempted from signing after being reviewed and approved by the ethics committee. (3) Glioma: (1) Between the ages of 14 and 80; (2) Patients diagnosed with glioma before surgery, with a maximum tumor diameter of = 3cm according to imaging evaluation, and planned for surgical resection; (3) The subjects voluntarily sign the informed consent form or are exempted from signing after being reviewed and approved by the ethics committee.
Exclusion criteria
Exclusion criteria: (1) Liver cancer: (1) Received anti-tumor treatment methods such as intervention, targeted therapy, and immunotherapy before surgery; (2) Patients with poor overall conditions and inability to tolerate surgery; (3) Those who are unable to obtain satisfactory specimens for both frozen pathology and paraffin pathology during surgery; (4) Those who are unable to obtain paraffin pathology reports; (5) Individuals who are currently participating in other clinical studies and may have an impact on this trial. (2) Breast cancer: (1) Inflammatory breast cancer; (2) Chest wall or skin invasion, local advanced breast cancer; (3) Widespread metastasis of axillary lymph nodes (stage IIIB and above); (4) Individuals with severe comorbidities (such as organ dysfunction, immune deficiency) and poor overall condition; (5) Unable to receive general anesthesia or surgical treatment; (6) Those who are unable to obtain satisfactory specimens for both frozen pathology and paraffin pathology during surgery; (7) Those who are unable to obtain paraffin pathology reports; (8) Individuals who are currently participating in other clinical studies and may have an impact on this trial. (3) Glioma: (1) Received anti-tumor treatment methods such as intervention, targeted therapy, and immunotherapy before surgery; (2) Patients with poor overall conditions and inability to tolerate surgery; (3) Those who are unable to obtain satisfactory specimens for both frozen pathology and paraffin pathology during surgery; (4) Those who are unable to obtain paraffin pathology reports; (5) Individuals who are currently participating in other clinical studies and may have an impact on this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tumor cell morphology; | — |
Secondary
| Measure | Time frame |
|---|---|
| sensitivity of identifying tumor cells;specificity of identifying tumor cells;accuracy of identifying tumor cells; | — |
Countries
China
Contacts
Public ContactJiayin Yang
West China Hospital of Sichuan University
Outcome results
None listed